These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 24591472)

  • 1. When are effective medications just too expensive?
    Mehta SJ; Asch DA
    Cleve Clin J Med; 2014 Mar; 81(3):173-5. PubMed ID: 24591472
    [No Abstract]   [Full Text] [Related]  

  • 2. Hepatitis C virus: here comes all-oral treatment.
    Dugum M; O'Shea R
    Cleve Clin J Med; 2014 Mar; 81(3):159-72. PubMed ID: 24591471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Daclatasvir: a team player rather than a prima donna in the treatment of hepatitis C.
    Aghemo A; De Francesco R
    Gut; 2015 Jun; 64(6):860-2. PubMed ID: 25193803
    [No Abstract]   [Full Text] [Related]  

  • 4. The high price of the new hepatitis C virus drugs.
    Steinbrook R; Redberg RF
    JAMA Intern Med; 2014 Jul; 174(7):1172. PubMed ID: 24798183
    [No Abstract]   [Full Text] [Related]  

  • 5. The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection.
    Ollendorf DA; Tice JA; Pearson SD
    JAMA Intern Med; 2014 Jul; 174(7):1170-1. PubMed ID: 24798321
    [No Abstract]   [Full Text] [Related]  

  • 6. [Programs for continuing medical education: a session; 2. Current therapy for chronic hepatitis C].
    Imamura M; Chayama K
    Nihon Naika Gakkai Zasshi; 2014 Mar; 103(3):625-9. PubMed ID: 24796128
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of chronic hepatitis C virus infection in the near future.
    Cheinquer H
    Ann Hepatol; 2013; 12(6):854-9. PubMed ID: 24114813
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatitis C genotype 1.
    Foster GR; De Silva S
    Curr Opin Infect Dis; 2014 Dec; 27(6):535-9. PubMed ID: 25304394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.
    Lawitz E; Sulkowski MS; Ghalib R; Rodriguez-Torres M; Younossi ZM; Corregidor A; DeJesus E; Pearlman B; Rabinovitz M; Gitlin N; Lim JK; Pockros PJ; Scott JD; Fevery B; Lambrecht T; Ouwerkerk-Mahadevan S; Callewaert K; Symonds WT; Picchio G; Lindsay KL; Beumont M; Jacobson IM
    Lancet; 2014 Nov; 384(9956):1756-65. PubMed ID: 25078309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A triple combination therapy of simeprevir, pegylated-interferon and ribavirin with chronic hepatitis C virus genotype 1 infection].
    Suzuki S; Izumi N
    Nihon Rinsho; 2015 Feb; 73(2):266-72. PubMed ID: 25764681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New drugs: simeprevir, sofosbuvir, and dolutegravir sodium.
    Hussar DA; Jin ZJ
    J Am Pharm Assoc (2003); 2014; 54(2):202-7. PubMed ID: 24632934
    [No Abstract]   [Full Text] [Related]  

  • 12. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thousands of patients in England to get new hepatitis C drugs.
    Kmietowicz Z
    BMJ; 2015 Jun; 350():h3222. PubMed ID: 26071408
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C.
    Younossi Z; Henry L
    Dig Liver Dis; 2014 Dec; 46 Suppl 5():S186-96. PubMed ID: 25458773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon-free hepatitis C treatment: one pill to fit all?
    Hellard ME; Doyle JS
    Lancet; 2014 Feb; 383(9916):491-2. PubMed ID: 24209978
    [No Abstract]   [Full Text] [Related]  

  • 16. [New hepatitis C treatments: pharmacological considerations and potential for drug interactions].
    Chtioui H; Buclin T; Moradpour D
    Rev Med Suisse; 2014 Sep; 10(440):1600-4, 1606. PubMed ID: 25276998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of chronic HCV with sofosbuvir and simeprevir in patients with cirrhosis and contraindications to interferon and/or ribavirin.
    Shiffman ML; James AM; Long AG; Alexander PC
    Am J Gastroenterol; 2015 Aug; 110(8):1179-85. PubMed ID: 26215530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The price of good health.
    Nat Med; 2014 Apr; 20(4):319. PubMed ID: 24710362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapy spectrum in hepatitis C extended. Newer NS3/4A protease inhibitor in chronic hepatitis C-GT1/4 infection].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():53. PubMed ID: 25026860
    [No Abstract]   [Full Text] [Related]  

  • 20. Special report: cost-effectiveness studies of new hepatitis C treatments.
    Mark DH;
    Technol Eval Cent Assess Program Exec Summ; 2015 Jan; 29(10):1-3. PubMed ID: 25962188
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.